Niosomes in sustained and targeted drug delivery: some recent advances

References

• Abd-Elbary A, El-Laithy HM, Tadros MI. (2008). Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm, 357, 189–198.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Katare OP, Vyas SP. (2001). Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm, 228, 43–52.
   PubMed Web of Science ®Google Scholar
• Aggarwal D, Garg A, Kaur IP. (2004). Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J Pharm Pharmacol, 56, 1509–1517.
   PubMed Web of Science ®Google Scholar
• Alcantar N, Dearborn K, VanAuker M, Toomey R, Hood E. (2008). Niosome-Hydrogel Drug Delivery. US Patent Application 20080050445.
   Google Scholar
• Alsarra IA. (2008). Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery. J Microencapsulation, 11, 1–7.
   PubMedGoogle Scholar
• Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. (2005). Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm, 59, 485–490.
   PubMed Web of Science ®Google Scholar
• Arien A, Dupuy B. (1997). Encapsulation of calcitonin in liposomes depends in the vesicle preparation method. J Microencapsulation, 14, 753–760.
   PubMed Web of Science ®Google Scholar
• Arunothayanun P, Uchegbu IF, Florence AT. (1999). Osmotic behaviour of polyhedral non-ionic surfactant vesicles (niosomes). J Pharm Pharmacol, 51, 651–657.
   PubMed Web of Science ®Google Scholar
• Azeem A, Jain N, Iqbal Z, Ahmad FJ, Aqil M, Talegaonkar S. (2008a). Feasibility of proniosomes based transdermal delivery of frusemide: formulation optimization and pharmacotechnical evaluation. Pharm Dev Technol, 13, 155–163.
   PubMed Web of Science ®Google Scholar
• Azeem A, Ahmad FJ, Khan ZI, Talegaonkar S. (2008b). Non-ionic surfactant vesicles as a carrier for transdermal delivery of frusemide. J Dispersion Sci Technol, 29, 723–730.
   Web of Science ®Google Scholar
• Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. (2009). Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm, 35, 525–547.
   PubMed Web of Science ®Google Scholar
• Azmin MN, Florence AT, Handjani-Vila RM, Stuart JFB, Vanlerberghe G, Whittaker JS. (1985). The effect of niosomes entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol, 37, 237–242.
   PubMed Web of Science ®Google Scholar
• Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. (1985). The preparation and properties of niosomes—non ionic surfactant vesicles. J Pharm Pharmacol, 37, 863–868.
   PubMed Web of Science ®Google Scholar
• Baillie AJ, Coombs GH, Dolan TF. (1986). Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stribogluconate. J Pharm Pharmacol, 38, 502–505.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the swollen phospholipids. J Mol Biol, 13, 238–252.
   PubMed Web of Science ®Google Scholar
• Begley DJ. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 48, 136–146.
   PubMed Web of Science ®Google Scholar
• Blazek-Welsh AI, Rhodes DG. (2001). SEM imaging predicts quality of niosomes from maltrodextrin based proniosomes. Pharm Res, 18, 656–661.
   PubMed Web of Science ®Google Scholar
• Cable C, Cassidy J, Kaye SB, Florence AT. (1988). Doxorubicin in cholesteryl polyoxyethylene modified niosomes. Evidence of enhancement of absorption in mice. J Pharm Pharmacol, 40, 31P.
   PubMedGoogle Scholar
• Caddeo C, Teskac K, Sinico C, Kristl J. (2008). Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm, 363, 183–191.
   PubMed Web of Science ®Google Scholar
• Carafa M, Santucci E, Lucania G. (2002). Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm, 231, 21–32.
   PubMed Web of Science ®Google Scholar
• Carter KC, Dolan TF, Alexander T, Baillie AJ, McColgan C. (1989). Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishamnia donovani infected BaLB/c mice. J Pharm Pharmacol, 41, 87–91.
   PubMed Web of Science ®Google Scholar
• Carter KC, Baillie AJ, Williams DM. (1999). Vesicle formulation. US Patent 5,869,091.
   Google Scholar
• Choi MJ, Maibach HI. (2005). Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol, 18, 209–219.
   PubMed Web of Science ®Google Scholar
• Cosco D, Celia C, Cilurzo F, Trapasso E, Paolino D. (2008). Colloidal carriers for the enhanced delivery through the skin. Expert Opin Drug Deliv, 5, 737–755.
   PubMed Web of Science ®Google Scholar
• Desai TR, Finlay WH. (2002). Nebulization of niosomal all-trans-retinoic acid: an inexpensive alternative to conventional liposomes. Int J Pharm, 241, 311–317.
   PubMed Web of Science ®Google Scholar
• Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. (2002). Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci, 251, 360–365.
   PubMed Web of Science ®Google Scholar
• Devi SG, Venkatesh, Udupa N. (2000). Niosomal sumatriptan succinate for nasal administration. Ind J Pharm Sci, 62, 479–481.
   Google Scholar
• Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, Lux G, Strunz U. (1978). Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut, 19, 1049–1053.
   Google Scholar
• Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olivier JC, Muller JM. (2004). Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm, 285, 77–85.
   PubMed Web of Science ®Google Scholar
• Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. (2006). Deformable liposomes and ethosomes: mechanism of enhanced drug delivery. Int J Pharm, 322, 60–66.
   PubMed Web of Science ®Google Scholar
• Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. (2001a). In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm, 215, 91–99.
   PubMed Web of Science ®Google Scholar
• Fang JY, Hong CT, Chiu WT, Wang YY. (2001b). Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm, 219, 61–72.
   PubMed Web of Science ®Google Scholar
• Frokjaer S, Hjorth EL, Worts O. (1984). Liposome Technology (Vol.1, pp. 235–245). Boca Raton, FL, CRC Press Inc.
   Google Scholar
• Garg A, Tisdale AW, Haidari E, Kokkoli E. (2009). Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm, 366, 201–210.
   PubMed Web of Science ®Google Scholar
• Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE. (1996). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA, 93, 427–432.
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm, 306, 71–82.
   PubMed Web of Science ®Google Scholar
• Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. (2007). Design and development of a proniosomal transdermal drug delivery system for captopril. Tropical J Pharm Res, 6, 687–693.
   Web of Science ®Google Scholar
• Gupta PN, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, Chatterji DP, Vyas SP. (2005). Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm, 293, 73–82.
   PubMed Web of Science ®Google Scholar
• Handjani-Vila RM, Ribier A, Rondot B, Vanlerberghe G. (1979). Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmetic Sci, 1, 303–314.
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhao F, Li N, Yang Y, Li K. (2002). Studies on a high encapsulation of colchicine by a noisome system. Int J Pharm, 244, 73–80.
   PubMed Web of Science ®Google Scholar
• Hassan M, Refai E, Andersson M, Schnell PO, Jacobsson H. (1994). In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. Nucl Med Biol, 21, 865–872.
   PubMed Web of Science ®Google Scholar
• Hofland HEJ, Boustra JA, Verhoef JC, Buckton G, Chowdry BZ, Ponec M, Junginger HE. (1992). Safety aspects of non-ionic surfactant vesicles—a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J Pharm Pharmacol, 44, 287–294.
   PubMed Web of Science ®Google Scholar
• Hofland HEJ, Boustra JA, Ponec M, Bodde HE, Spies F, Coos VJ, Junginger HE. (1999). Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: a survey of toxicological aspects and ultrastructural changes in stratum corneum. J Control Release, 16, 155–168.
   Google Scholar
• Hood E, Strom JA, VanAuker M. (2006). Ultrasound Enhancement of Drug Release Across Non-Ionic Surfactant Membranes. US Patent Application 20060292211.
   Google Scholar
• Hood E, Gonzalez M, Plaas A, Strom J, VanAuker M. (2007 ). Immuno-targeting of nonionic surfactant vesicles to inflammation. Int J Pharm, 339, 222–230.
   PubMed Web of Science ®Google Scholar
• Hu C, Rhodes DG. (1999). Proniosomes: a novel drug carrier preparation. Int J Pharm, 185, 23–35.
   PubMed Web of Science ®Google Scholar
• Jain S, Singh P, Mishra V, Vyas SP. (2005). Mannosylated niosomes as adjuvant–carrier system for oral genetic immunization against Hepatitis B. Immunol Lett, 101, 41–49.
   PubMed Web of Science ®Google Scholar
• Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. (2008). Effective delivery of an angiogenesis inhibitor by neovessel targeted liposomes. Int J Pharm, 360, 219–224.
   PubMedGoogle Scholar
• Kaur IP, Garg A, Singla AK, Aggarwal D. (2004). Vesicular systems in ocular delivery: an overview. Int J Pharm, 269, 1–14.
   PubMed Web of Science ®Google Scholar
• Khandare JN, Madhavi G, Tamhankar BM. (1994). Niosomes novel drug delivery system. The Eastern Pharmacist, 37, 61–64.
   Google Scholar
• Kiwada H, Niimura H, Fujisaki Y, Yamada S, Kato Y. (1985). Application of synthetic alkyl glycoside vesicles as drug carriers. Chem Pharm Bull, 33, 753–759.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Jain SK, Pancholi SS, Agarwal S, Saraf DK, Agarwal GP. (2003). Provesicular transdermal drug delivery system of ethinylestradiol and levonorgestrel for contraception and hormone replacement therapy. Indian J Pharm Sci, 65, 620–627.
   Google Scholar
• Lelièvre V, Pineau N, Du J, Wen CH, Nguyen T, Janet T, Muller JM, Waschek JA. (1998). Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. J Biol Chem, 273, 19685–19690.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Kessler JF, Meyskens FL. (1987). Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep, 71, 493–515.
   PubMedGoogle Scholar
• Liu T, Guo R. (2007). Structure and transformation of the niosome prepared from PEG 6000/Tween 80/Span 80/H2O lamellar liquid crystal. Colloids Surf A, 295, 130–134.
   Web of Science ®Google Scholar
• Liu T, Guo R, Hua W, Qiu J. (2007). Structure behaviors of hemoglobin in PEG 6000/Tween 80/Span 80/H2O niosome system. Colloids Surf A, 293, 255–261.
   Web of Science ®Google Scholar
• Lokshin A, Zhang H, Mayotte J, Lokshin M, Levitt ML. (1999). Early effects of retinoic acid on proliferation, differentiation and apoptosis in non-small cell lung cancer cell line. Anticancer Res, 19, 5251–5254.
   PubMed Web of Science ®Google Scholar
• Magistretti PJ, Morrison JH, Shoemaker WJ, Sapin V, Bloom FE. (1981). Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. Proc Natl Acad Sci USA, 78, 6535–6539.
   PubMed Web of Science ®Google Scholar
• Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. (2002). Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm, 234, 237–248.
   PubMed Web of Science ®Google Scholar
• Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda AM. (2003). Niosomes as carriers for tretinoin II. Influence of vesicular incorporation on tretinoin photostability. Int J Pharm, 260, 261–272.
   PubMed Web of Science ®Google Scholar
• Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. (2006). Niosomes as carriers for tretinoin III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm, 311, 11–19.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Jantrawut P, Manosroi J. (2008). Antiinflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm, 360, 156–163.
   PubMed Web of Science ®Google Scholar
• Maver LD, Bally MB, Hope MJ, Cullis PR. (1985). Biochem Biophys Acta, 816, 294–302.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Hope MJ, Cullis PR. (1985). Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochem Biophys Acta, 816, 294–302.
   PubMed Web of Science ®Google Scholar
• Mayne ST. (1996). Beta-carotene, carotenoids and disease prevention in humans. FASEB J, 10, 690–701.
   Google Scholar
• Mokhtar M, Sammour OA, Hammad MA, Megrab NA. (2008). Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm, 361, 104–111.
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Patra B, Layek B, Mukherjee A. (2007). Sustained release of acyclovir from nano-liposomes and nano-niosomes. Int J Nanomedicine, 2, 213–225.
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54, 131–155.
   PubMed Web of Science ®Google Scholar
• Mura S, Pirot F, Manconi M, Falson F, Fadda AM. (2007). Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J Drug Target, 15, 101–108.
   PubMed Web of Science ®Google Scholar
• Murdan S, Gregoriadis G, Florence AT. (1999). Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens? Eur J Pharm Sci, 8, 177–185.
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. (1999 ). Niosomal delivery of 5-fluorouracil. J Microencapsulation, 16, 731–740.
   PubMed Web of Science ®Google Scholar
• Ning M, Guo Y, Pan H, Chen X, Gu Z. (2005). Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm, 31, 375–383.
   PubMed Web of Science ®Google Scholar
• Ogiso T, Niinaka N, Iwaki M. (1996). Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci, 85, 57–64.
   PubMed Web of Science ®Google Scholar
• Palozza P, Muzzalupo R, Trombino S, Valdannini A, Picci N. (2006). Solubilization and stabilization of β-carotene in niosomes: delivery to cultured cells. Chem Phys Lipids, 139, 32–42.
   PubMed Web of Science ®Google Scholar
• Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. (2008). Innovative bola surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm, 353, 233–242.
   PubMed Web of Science ®Google Scholar
• Pardakhty A, Varshosaz J, Rouholamini A. (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 328, 130–141.
   PubMed Web of Science ®Google Scholar
• Rai K, Gupta Y, Jain A, Jain SK. (2008). Transferosomes: self optimizing carriers for bioactives. PDA J Pharm Sci Technol, 62, 362–379.
   PubMedGoogle Scholar
• Rao Y, Zheng F, Zhang X, Gao J, Liang W. (2008). In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS Pharm Sci Tech, 9, 860–865.
   PubMed Web of Science ®Google Scholar
• Reddy DR, Udupa N. (1993). Formation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm, 19, 843–852.
   Web of Science ®Google Scholar
• Rentel CO, Bouwstra JA, Naisbett B, Junginger HE. (1999). Niosomes as a novel peroral vaccine delivery system. Int J Pharm, 186, 161–167.
   PubMed Web of Science ®Google Scholar
• Rogerson A, Cummings J, Willmott N, Florence AT. (1988). The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol, 40, 337–342.
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Jayakar B, Ghosal SK. (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage and in vitro release. Drug Dev Ind Pharm, 26, 217–222.
   PubMed Web of Science ®Google Scholar
• Saettone MF, Perini G, Carafa M, Santucci E, Alhaique F. (1996). Non-ionic surfactant vesicles as ophthalmic carriers for cyclopentolate. A preliminary evaluation. STP Pharma Sci, 6, 94–98.
   Google Scholar
• Schreier H, Bouwstra J. (1994). Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release, 30, 1–15.
   Web of Science ®Google Scholar
• Shahiwala A, Misra A. (2002). Studies in topical application of niosomally entrapped nimesulide. J Pharm Pharmaceut Sci, 5, 220–225.
   PubMed Web of Science ®Google Scholar
• Shi B, Fang C, Pei Y. (2006). Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci, 95, 1873–1887.
   PubMed Web of Science ®Google Scholar
• Solanki AB, Parikh JR, Parikh RH. (2007). Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS Pharm Sci Tech, 8, E1–E7.
   PubMed Web of Science ®Google Scholar
• Solanki AB, Parikha J, Parikh R. (2008). Preparation, characterization, optimization, and stability studies of aceclofenac proniosomes. Iranian J Pharm Res, 7, 237–246.
   Web of Science ®Google Scholar
• Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. (2006). Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm, 323, 1–10.
   PubMed Web of Science ®Google Scholar
• Talsma H, Steenbergen MJV, Borchert JCH, Crommelin DJA. (1994). A novel technique for the one-step preparation of liposomes and non ionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: the “bubble” method. J Pharm Sci, 83, 276–280.
   Google Scholar
• Uchegbu IF, Vyas SP. (1998). Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm, 172, 33–70.
   Web of Science ®Google Scholar
• Uchegbu IF, Bouwstra JA, Florence AT. (1992). Large disc-shaped structures (discomes) in non ionic surfactant vesicle to micelle transitions. J Phys Chem, 96, 10548–10553.
   Web of Science ®Google Scholar
• Uchegbu IF, Duncan R. (1997). Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm, 155, 7–17.
   Web of Science ®Google Scholar
• Varshosaz J, Pardakhty A, Mohsen S, Baharanchi H. (2005). Sorbitan monopalmitate-based proniosomes for transdermal delivery of chlorpheniramine maleate. Drug Dev, 12, 75–82.
   Google Scholar
• Vora B, Khopade AJ, Jain NK. (1998). Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release, 54, 149–165.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Khar RK. (2002). Niosomes, Targeted and Controlled Drug Delivery, Novel Carrier Systems (1st ed., pp. 249–279). New Delhi: CBS Publishers.
   Google Scholar
• Vyas SP, Mysore N, Jaitely V, Venkatesan N. (1998). Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie, 53, 466–469.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, Gupta PN, Rawat A, Dubey P. (2005). Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm, 296, 80–86.
   PubMed Web of Science ®Google Scholar
• Weiner AL. (1994). Liposomes for protein delivery: selecting manufacture and development processes. Immuno Methods, 4, 201–209.
   Google Scholar
• Werle M, Takeuchi H. (2009). Chitosan aprotinin coated liposomes for oral peptide delivery: development, characterization and in vivo evaluation. Int J Pharm, 370, 26–32.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, Bouwistra JA. (1992). Niosomes for oral delivery of peptide drugs. J Control Release, 21, 145–153.
   Web of Science ®Google Scholar
• Yoshioka T, Sternberg B, Florence AT. (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm, 105, 1–6.
   Web of Science ®Google Scholar
• Zheng X, Lu J, Deng L, Xiong Y, Chen J. (2009). Preparation and characterization of magnetic cationic liposome in gene delivery. Int J Pharm, 366, 211–217.
   PubMed Web of Science ®Google Scholar
• Zhu L, Huo Z, Wang L, Tong X, Xiao Y, Ni K. (2009). Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm, 370, 136–143.
   PubMed Web of Science ®Google Scholar
• Zuidam NJ, Lee SSL, Crommelin DJA. (1993). Sterilization of liposomes by heat treatment. Pharm Res, 10, 1591–1596.
   PubMed Web of Science ®Google Scholar